Syndax Pharmaceuticals (SNDX) began trading on Nasdaq on 3 March 2016

• Syndax Pharmaceuticals is a cancer-focused biotechnology company.
• IPO issue price of $12.
• Syndax sold 4.4 million shares to raise $52.8 million. 
• The company had previously set a price range of $14 to $16. Morgan Stanley, Citigroup, JMP Securities and Oppenheimer were the underwriters for the offering.

Ticker:  SNDX

monthly; Dec 2016; 9 months after IPO

March 2017; 1 year after IPO

Description

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Address

400 Totten Pond Rd Ste 110
WALTHAM, MA 02451-2040
United States 

Key stats and ratios

	Q4 (Dec '16)	2016
Net profit margin	-3545.90%	-3645.25%
Operating margin	-3652.79%	-3587.38%
EBITD margin	-	-3580.08%
Return on average assets	-38.26%	-44.71%
Return on average equity	-48.75%	-
Employees	17

Innocoll (INNL) began trading on the NASDAQ on 25 July 2014

The Irish drug company makes after-surgery pain treatment and medicine for diabetic foot infections. It raised $58.5 million after pricing 6.5 million American depositary shares at $9 per ADS. It previously expected to raise more money, between $69.6 million and $80.3 million, in a larger offering of shares. Innocoll plans to use the cash it raised to develop its treatments and increase its manufacturing infrastructure. Its shares, which are trading on the Nasdaq exchange under the symbol "INNL," closed flat at $9. During trading hours, the stock fell as low as $8.58 and rose as high as $9.51.

Parnell Pharmaceuticals began trading on the NASDAQ on 18 June 2014

Parnell Pharmaceuticals Holdings Ltd. operates as an integrated pharmaceutical company that develops animal health solutions. It operates in four segments: Companion Animal, Production Animal U.S., Production Animal Rest of World, and Manufacturing Operations. The company's marketed products include reproductive hormone products comprising estroPLAN and GONAbreed that are used in breeding programs to increase pregnancy rates in dairy and beef cows; Zydax, a patented disease-modifying product for the treatment of osteoarthritis (OA) in dogs and horses; Glyde, a nutraceutical product is a combination of glycoaminoglycans for the treatment of OA in dogs; and Tergive, an injectable NSAID that contains carprofen. It is also developing GONADOPRO combination formulation of gonadorelin acetate; PAR081, a propofol-based product for general anesthesia and sedation in dogs and cats; PAR101 to treat laminitis in horses and diabetes in dogs; PAR121 for bone-related diseases and injuries in dogs, cats, and horses; PAR122 for atopic dermatitis and other dermatological conditions; and PAR061, an injectable antibiotic prodrug. The company markets its products in Australia, New Zealand, Singapore, Hong Kong, Dubai, the United States, Canada, the Middle East, and Africa. The company was formerly known as Parnell Pharmaceuticals Holdings Pty Ltd and changed its name to Parnell Pharmaceuticals Holdings Ltd. in April 2014. The company was founded in 1986 and is headquartered in Alexandria, Australia.

Kite Pharma (KITE) began trading on the NASDAQ on 20 June 2014

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT). eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs, or T cell receptors, or TCRs). These modified T cells are designed to recognize and destroy cancer cells. The Company funds multiple Phase I-2a clinical trials with CAR- and TCR-based therapies that are being conducted by its collaborator, the Surgery Branch of the National Cancer Institute (NCI). The Company plans to conduct a Phase I-2 clinical trial for its lead product candidate KTE-C19, a CAR-based therapy, in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL).

Address

2225 COLORADO AVENUE
SANTA MONICA, CA 90404
United States

Website 

http://www.kitepharma.com

Key stats and ratios

	Q1 (Mar '14)	2013
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-58.18%	-39.94%
Return on average equity	-73.75%	-53.06%
Employees	19

Cerulean Pharma (CERU) began trading on the NASDAQ on 10 April 2014

Cerulean Pharma Inc. is a clinical-stage oncology-focused company applying its tumor targeting platform. The Company’s nanopharmaceutical product candidates consist of polymers that are linked to anti-cancer therapeutics, or payloads. Its lead product candidate, CRLX101, is in Phase II clinical development and has the potential to address cancer therapies. CRLX301, the second product candidate, is a nanopharmaceutical with docetaxel, a microtubule stabilizer, as its anti-cancer payload. The clinical development of CRLX101 is focused on cancer indications. A two-part Phase II open-label IST of CRLX101 is being conducted in patients with relapsed ovarian cancer. CRLX301 is designed to act as a tubulin inhibitor, capitalizes on its payload, docetaxel.

Address

5th Floor, 840 Memorial Drive
CAMBRIDGE, MA 02139
United States

Website 

http://ceruleanrx.com

Key stats and ratios

	Q1 (Mar '14)	2013
Net profit margin	-6200.00%	-285716.70%
Operating margin	-6293.62%	-264333.30%
EBITD margin	-	-261050.00%
Return on average assets	-125.13%	-140.01%
Return on average equity	-	-
Employees	21

SCYNEXIS (SCYX) began trading on the NASDAQ on 2 May 2014

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 represents a new chemical class of drugs designed to block an established target in infectious fungi. The Company is developing both an IV and oral formulation of SCY-078. SCY-078 is a potent inhibitor of the synthesis of the fungal cell wall polymer glucan, an essential component of Candida and Aspergillus species. The compound is derived, by chemical modification, from a natural product that shows anti-fungal activity against Candida and Aspergillus through inhibition of glucan synthesis, like the echinocandin class.

Address

3501-C TRICENTER BLVD
DURHAM, NC 27713
United States 

Website 

http://www.scynexis.com

Flexion Therapeutics (FLXN) began trading on the NASDAQ on 12 February 2014

Description

Flexion Therapeutics, Inc. (Flexion Therapeutics) is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis, referred to as OA. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. FX007 is a locally administered TrkA receptor antagonist for persistent relief of post-operative pain, including in patients who have received total joint replacement, also referred to as total joint arthroplasty (TJA).

Address

Suite 301, 10 Mall Road
BURLINGTON, MA 01803
United States

Website 

http://flexiontherapeutics.com

Key stats and ratios

	Q3 (Sep '13)	2012
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-84.08%	-73.18%
Return on average equity	-	-
Employees	16

Zoetis (ZTS) began trading on the NYSE on 1 February 2013

Description

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The primary livestock species are cattle (both beef and dairy), swine, poultry, sheep and fish, and the primary companion animal species are dogs, cats and horses. In February 2014, Benchmark Holdings PLC purchased aquaculture vaccine and development assets from animal health company Zoetis Inc.

Address

100 Campus Drive
FLORHAM PARK, NJ 07932
United States

Key stats and ratios

	Q3 (Sep '13)	2012
Net profit margin	11.88%	10.06%
Operating margin	16.77%	16.37%
EBITD margin	-	25.25%
Return on average assets	8.39%	7.28%
Return on average equity	63.96%	11.26%
Employees	9,300

GW Pharmaceuticals plc (GWPH) began trading on the NASDAQ on 29 April 2013

** daily ** 

** weekly **

GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, is engaged in discovering, developing, and commercializing cannabinoid prescription medicines. The company operates through three segments: Sativex Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company's product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

Address

Porton Down Science Park
SALISBURY, ENG SP4 0JQ
United Kingdom

Website 

http://www.gwpharm.com

Key stats and ratios

		2012
Net profit margin	-	7.52%
Operating margin	-	3.15%
EBITD margin	-	1.17%
Return on average assets	-	6.07%
Return on average equity	-	12.81%
Employees	182

Relypsa (RLYP) began trading on the NASDAQ on 15 November 2013

1/24/14 update

Jan 2014

Nov 2013

Description

Relypsa, Inc. is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Company has completed its two-part pivotal Phase III trial of its product candidate, patiromer, for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. The Company has designed patiromer to efficiently bind and remove potassium from the body, thereby treating hyperkalemia. The Company has conducted a clinical development program, in which daily administration of patiromer has been observed by the Company to lower, and maintain control of, serum potassium levels in hyperkalemic subjects with an acceptable safety and tolerability profile.

Address

700 Saginaw Drive
REDWOOD CITY, CA 94063
United States 

Website 

http://www.relypsa.com

Key stats and ratios

	Q3 (Sep '13)	2012
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-314.24%	-92.43%
Return on average equity	-	-
Employees	69

Karyopharm Therapeutics (KPTI) began trading on the NASDAQ on 6 November 2013

Ticker:  KPTI

Jan 2014 update

Description

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The Company has discovered and developed small molecule, Selective Inhibitors of Nuclear Export (SINE), compounds that inhibit the nuclear export protein XPO1. The Company’s drug candidate, Selinexor (KPT-330), is an XPO1 inhibitor, evaluated in multiple open-label Phase 1 clinical trials in patients with heavily pretreated relapsed or refractory hematological and solid tumor malignancies. As of September 20, 2013, the Company had administered Selinexor to over 170 patients in these trials.

Address

2 Mercer Road
NATICK, MA 01760
United States

Website 

www.karyopharm.com

Key stats and ratios

	Q2 (Jun '13)	2012
Net profit margin	-3409.84%	-2505.99%
Operating margin	-3410.11%	-2506.31%
EBITD margin	-	-2487.07%
Return on average assets	-	-372.30%
Return on average equity	-	-
Employees	23

Evoke Pharma (EVOK) began trading on the NASDAQ on 25 September 2013

Jan 2014 update

Description

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The Company’s lead product candidate, EVK-001, is in late stage clinical testing. EVK-001 is a formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration. Gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis results in food remaining in the stomach for a longer time than normal, yielding a variety of symptoms.

Address

Suite 385, 12555 High Bluff Drive
SAN DIEGO, CA 92130
United States

Website 

http://www.evokepharma.com

Key stats and ratios

	Q2 (Jun '13)	2012
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-55.40%	-395.07%
Return on average equity	-	-
Employees	2

Acceleron Pharma (XLRN) began trading on the NASDAQ on 18 September 2013

• Note:Acceleron Pharma operated as a public company focused on rare and serious diseases until it was acquired by Merck in November 2021 for approximately $11.5 billion

Jan 2014 update

Description

Acceleron Pharma Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company’s research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.

Address

128 Sidney Street
CAMBRIDGE, MA 02139
United States 

Website 

http://www.acceleronpharma.com

Key stats and ratios

	Q3 (Sep '13)	2012
Net profit margin	-433.56%	-213.60%
Operating margin	-422.32%	-204.17%
EBITD margin	-	-13.39%
Return on average assets	-88.78%	-52.98%
Return on average equity	-	-
Employees	79

Tetralogic Pharmaceuticals (TLOG) began trading on the NASDAQ on 12 December 2013

• The stock reached $9.71 in 2013 and $5.19 in 2014 during its active clinical development phase.
• TetraLogic restructured its convertible senior notes and voluntarily delisted its common stock from NASDAQ, moving to the OTC market under the ticker TLOG.PK.

TetraLogic Pharmaceuticals Corporation (TetraLogic) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases (SMAC)-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct. Birinapant, its clinical-stage product candidate, is being tested in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The Company’s clinical trials of birinapant have enrolled over 275 subjects. The Company’s lead program is colorectal cancer (CRC), where it has substantially completed a Phase I/II clinical trial. TetraLogic's lead Smac mimetic drug, birinapant (formerly TL32711), is in Phase II clinical trials and is being developed for both solid tumors and hematological malignancies as a single agent and in combination with several standard-of-care cancer therapies.

Address

343 PHOENIXVILLE PIKE
MALVERN, PA 19355
United States

Website 

www.tetralogicpharma.com

Fate Therapeutics (FATE) began trading on the NASDAQ on 10 October 2013

Description

Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Its approaches utilize pharmacologic modalities, including small molecules and therapeutic proteins, and biological mechanisms to enhance the therapeutic potential of adult stem cells.

Address

Suite 200, 3535 General Atomics Court
SAN DIEGO, CA 92121
United States 

Website 

www.fatetherapeutics.com

Key stats and ratios

	Q2 (Jun '13)	2012
Net profit margin	-1908.28%	-533.30%
Operating margin	-1472.07%	-519.85%
EBITD margin	-	-485.28%
Return on average assets	-352.05%	-150.45%
Return on average equity	-	-
Employees	33

Aerie Pharmaceuticals (AERI) began trading on the NASDAQ on 25 October 2013

Description

Aerie Pharmaceuticals, Inc. is a United States-based company. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidate, AR-13324, is a dual-action drug class. AR-13324 is a once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. It acts through the inhibition of both Rho Kinase (ROCK) and the Norepinephrine Transporter (NET). Its dual-action product has completed phase-II development. The Company’s product candidate PG324 is a fixed combination of dual-action AR-13324 with latanoprost formulated in a single eye drop and is designed to intraocular pressure by reducing fluid inflow while also opening both of the eye’s fluid drains.

Address

Suite 15, 135 US Highway 206
BEDMINSTER, NJ 92660
United States

Website 

www.aeriepharma.com

Key stats and ratios

	Q2 (Jun '13)	2012
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-	-160.39%
Return on average equity	-	-
Employees	23